Pfizer will begin selling a cheaper version of one of Johnson & Johnson’s (J&J) most popular products.  Pfizer announced Monday that it will begin shipment of Inflectra, a biosimilar of J&J’s rheumatoid-arthritis treatment Remicade, to wholesalers in the United States in late November 2016. The company says Inflectra will be the first biosimilar monoclonal antibody (mAb)…